OUTLINE:
Patients receive standard of care radium Ra 223 dichloride given by intravenous (IV) bolus every 4 weeks for up to 6 cycles. Patients undergo collection of blood every 1-3 months during radium Ra 223 dichloride treatment.
After completion of study, patients are followed up every 3 months for up to 5 years from the date of treatment completion.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patient must be \>= 18 years of age
Patient must have histopathologic diagnosis of prostate cancer
Patient must have castration-resistant prostate cancer
Patient must have radiographic evidence of bone metastasis
Patients must be symptomatic from prostate cancer
Patient must have plans to undergo treatment with radium-223
Patient must have a PSA level \>= 10 ng/mL
Patient must have castrate testosterone levels demonstrated within the last 3 months prior to screening
Patient must have anticipated survival \> 3 months
Patient must be willing and able to authorize consent
Patient must be willing and able to comply with the protocol, including follow-up visits
You may not be if
Patient must not have visceral metastasis
Patients on regimens of radium-223 in combination with other antineoplastic agents are excluded
\* Bone-targeted only therapy (e.g. denosumab or zoledronic acid) will be allowed
Patients who have received prior radium-223
Patients who have received prior platinum containing chemotherapy
Absolute neutrophil count (ANC) \< 1.5 x 10\^9/L
Hemoglobin (HB) \< 9 g/dL
Platelets (PLT) \< 100 x 10\^9/L
Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation
Clareo Health | Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
